|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 373.25 Million
|
|
Market Size (2030)
|
USD 531.94 Million
|
|
CAGR (2025-2030)
|
6.04%
|
|
Fastest Growing Segment
|
Proliferative DR
|
|
Largest Market
|
Kanto
|
Market Overview
Japan Diabetic Retinopathy Therapeutic Market was valued
at USD 373.25 Million in 2024 and is expected to reach USD 531.94 Million
by 2030 with a CAGR of 6.04% during the forecast period. The Japan diabetic
retinopathy therapeutic market is driven by several key factors. The rising
prevalence of diabetes in Japan significantly increases the demand for diabetic
retinopathy treatments, as this condition is a common complication of diabetes.
Advancements in therapeutic options, including novel anti-VEGF (vascular
endothelial growth factor) therapies and improved laser treatments, enhance
treatment efficacy and patient outcomes. Increasing awareness and early
detection through advanced diagnostic tools contribute to timely treatment
initiation. The growing aging population, which is more susceptible to diabetic
retinopathy, further fuels market growth. Supportive healthcare policies and
insurance coverage for advanced therapies make treatments more accessible to
patients, thereby expanding the market. These factors collectively drive the
growth and development of the diabetic retinopathy therapeutic market in Japan.
Key Market Drivers
Rising Prevalence of Diabetes
The increasing prevalence of diabetes in Japan is a
significant driver of the diabetic retinopathy therapeutic market, reflecting a
broader global trend. Diabetes, particularly Type 2 diabetes, has become
increasingly common in Japan due to several interrelated factors. The aging
population is a primary contributor; as people live longer, they are more
susceptible to developing chronic conditions, including diabetes. Urbanization
and lifestyle changes, such as shifts towards sedentary habits and diets high
in processed foods, have exacerbated the incidence of Type 2 diabetes. Type 2
diabetes is characterized by insulin resistance and eventually leads to higher
blood glucose levels. Over time, elevated glucose levels damage various organs
and tissues, including the eyes, leading to complications such as diabetic
retinopathy. Diabetic retinopathy is a serious condition where high blood sugar
levels cause damage to the blood vessels in the retina, potentially leading to
vision impairment and blindness if left untreated. This connection between
diabetes and diabetic retinopathy underscores the importance of addressing both
conditions simultaneously. In recent years, Japan has experienced a sharp
rise in diabetes cases, becoming one of the countries most impacted by the
global diabetes epidemic. The Ministry of Health, Labour and Welfare (MHLW) has
designated diabetes as a key healthcare priority. While Type 1 diabetes is
relatively uncommon in Japan, Type 2 diabetes is prevalent among both adults
and children. The surge in diabetes cases is attributed to increased longevity
and lifestyle changes, resulting in a growing number of individuals with Type 2
diabetes. Currently, around 13.5% of the Japanese population is affected by
either Type 2 diabetes or impaired glucose tolerance. This high prevalence
imposes a substantial economic burden, with diabetes expenditures accounting
for up to 6% of Japan's total healthcare budget.
The rise in diabetes cases translates directly into
an increased prevalence of diabetic retinopathy. According to recent
epidemiological data, the prevalence of diabetes in Japan has seen a marked
increase, with the number of individuals affected growing steadily. As the
diabetic population expands, so does the need for effective treatments to
manage and mitigate the impact of diabetic retinopathy. This growing demand
drives the market for therapeutic interventions designed to treat and manage
diabetic retinopathy, including advanced pharmaceuticals, laser therapies, and
surgical options. Japan's healthcare system is responding to this rising demand
by focusing on both preventive and therapeutic measures. The government and
healthcare providers are increasingly prioritizing the management of diabetic
retinopathy as part of broader diabetes care strategies. Efforts to improve
early detection and treatment are essential to address the rising prevalence of
the condition. This includes investing in advanced diagnostic technologies and
expanding access to specialized care for diabetic patients.
Advancements in Treatment Technologies
Technological advancements are dramatically
transforming the diabetic retinopathy therapeutic market in Japan, driving both
innovation and growth. Recent developments in this field have revolutionized
the management of diabetic retinopathy, particularly through the introduction
and refinement of novel therapies and techniques. One of the most significant
advancements is the development and approval of anti-VEGF (vascular endothelial
growth factor) agents. These therapies have fundamentally changed the landscape
of diabetic retinopathy treatment by targeting and inhibiting specific growth
factors responsible for the progression of the disease. Anti-VEGF agents work
by blocking the action of VEGF, a protein that stimulates the formation of
abnormal blood vessels in the retina. This mechanism helps to prevent further damage
by reducing the formation of these abnormal vessels and decreasing fluid
leakage, thereby improving vision outcomes for patients.
In addition to anti-VEGF therapies, advancements in
laser treatment technologies have also played a crucial role in the management
of diabetic retinopathy. Traditional laser treatments, such as focal and pan
retinal photocoagulation, have been refined to become less invasive and more
effective. Newer laser techniques offer enhanced precision, targeting only the
damaged areas of the retina while minimizing damage to surrounding healthy
tissue. These improvements lead to better efficacy and greater patient comfort,
as patients experience fewer side effects and faster recovery times. The
refinement of laser technologies represents a significant leap forward in the
treatment of diabetic retinopathy, contributing to improved visual outcomes and
quality of life for patients. The field has seen substantial progress in
surgical techniques, which now offer more effective and less invasive options
for treating advanced stages of diabetic retinopathy. Innovations in surgical
methods, such as improved vitrectomy techniques, enable surgeons to more
precisely remove vitreous gel and scar tissue from the retina. These
advancements have led to better surgical outcomes and reduced complications,
further enhancing the therapeutic options available for patients with diabetic
retinopathy.
Increased Awareness and Early Diagnosis
Awareness and early diagnosis are pivotal drivers
of the diabetic retinopathy therapeutic market in Japan, significantly
influencing the way the condition is managed and treated. Recognizing the
critical role that education plays in controlling diabetic retinopathy, Japan
has made substantial strides in raising awareness among both healthcare
professionals and the general public about the importance of regular eye
screenings for diabetic patients. The government, along with various health
organizations, has implemented extensive educational campaigns aimed at
informing people about the risks associated with diabetic retinopathy and the
benefits of early detection. These initiatives highlight the direct link
between diabetes management and eye health, stressing that timely intervention
can prevent severe complications, including vision loss.
In recent years, Japan has also invested in
programs designed to enhance the understanding of diabetic retinopathy among
healthcare providers. Training and continuing education for ophthalmologists,
endocrinologists, and primary care physicians focus on the latest diagnostic
techniques and treatment options. By equipping healthcare professionals with
up-to-date knowledge and skills, these programs ensure that patients receive
timely and accurate assessments, which is crucial for effective disease
management. Public health campaigns have been instrumental in increasing
patient awareness about the importance of regular eye check-ups, encouraging
those with diabetes to seek routine screening as part of their overall health
management.
The advancement of diagnostic technologies has
further supported these awareness efforts by making early detection of diabetic
retinopathy more accessible and accurate. Optical coherence tomography (OCT)
and advanced fundus photography represent significant technological
improvements that enhance the precision of diabetic retinopathy diagnosis. OCT,
for instance, provides detailed cross-sectional images of the retina, allowing
for the early detection of changes associated with diabetic retinopathy before
symptoms become evident. Advanced fundus photography captures high-resolution
images of the retina, facilitating the identification of early signs of retinal
damage. These technologies have revolutionized the diagnostic process, enabling
healthcare providers to detect diabetic retinopathy at earlier stages and
initiate appropriate treatment sooner.
Aging Population
Japan's rapidly aging population is a critical
driver of the diabetic retinopathy therapeutic market. The country faces a
demographic shift where the proportion of elderly individuals is increasing
significantly. This aging trend has profound implications for public health,
particularly regarding chronic conditions like diabetes and its associated
complications, including diabetic retinopathy. As the population ages, the
prevalence of diabetes and related health issues, such as diabetic retinopathy,
rises correspondingly. This demographic transition necessitates a focused
approach to managing diabetes and its complications among the elderly, thereby
fueling the demand for specialized therapeutic solutions. The International
Diabetes Federation projected that the global population with diabetes mellitus
(DM) would reach 463 million in 2019 and 700 million by 2045. In Japan, there
are currently 10 million individuals living with DM, with 3 million of them
also suffering from diabetic retinopathy (DR), which ranks as the third most
common cause of visual impairments, affecting 12.8% of the population.
Older adults are inherently more susceptible to
chronic diseases due to age-related physiological changes and comorbidities.
Diabetes, particularly Type 2 diabetes, is prevalent among the elderly, and
managing this condition becomes increasingly complex with advancing age. The
aging process often leads to a decline in physiological functions, which can
exacerbate the effects of diabetes and its complications. Consequently, elderly
patients with diabetes are at a higher risk of developing diabetic retinopathy,
a serious condition that can lead to vision impairment or blindness if not
managed effectively. In response to this growing need, Japan’s healthcare
system is adapting to better address the challenges posed by an aging
population. The increasing prevalence of diabetic retinopathy among the elderly
has led to a greater focus on geriatric care within the healthcare sector.
Healthcare providers are now more attuned to the specific needs of older
diabetic patients, which has led to the development of targeted management
strategies and specialized treatments designed for this demographic. This
includes advancements in diagnostic tools, therapeutic interventions, and
patient management protocols that cater specifically to the elderly.
Download Free Sample Report
Key Market Challenges
High Cost of Advanced Therapies
The high cost of advanced diabetic retinopathy
therapies poses a significant challenge for the Japanese market. Innovative
treatments, such as anti-VEGF (vascular endothelial growth factor) injections
and advanced laser therapies, often come with substantial price tags. These
costs can be burdensome for both patients and healthcare systems, especially
considering the ongoing need for multiple treatment sessions to manage diabetic
retinopathy effectively. While Japan's healthcare system provides substantial
coverage, the financial strain on public and private insurance can be
considerable. This high cost barrier can limit patient access to cutting-edge
therapies and potentially delay treatment, impacting overall disease management
and patient outcomes. The economic pressure of these treatments necessitates
careful consideration of pricing strategies and insurance coverage to ensure
equitable access for all patients.
Limited Access to Specialized Care
Access to specialized care for diabetic retinopathy
can be uneven across Japan, particularly between urban and rural areas. While
major cities like Tokyo and Osaka have numerous facilities equipped with the
latest diagnostic and therapeutic technologies, patients in remote or less
populated regions may face challenges accessing specialized care. This
geographic disparity can lead to delays in diagnosis and treatment,
exacerbating the progression of diabetic retinopathy and negatively affecting
patient outcomes. The shortage of specialists and advanced facilities in rural
areas further complicates this issue, making it difficult for patients to
receive timely and effective care. Addressing these disparities requires a
concerted effort to improve healthcare infrastructure and ensure that advanced
diabetic retinopathy treatments are available across all regions of Japan.
Key Market Trends
Research & Development Investments
Investment in research and development (R&D) is
a crucial driver of the diabetic retinopathy therapeutic market, propelling the
industry forward by introducing innovative treatments and enhancing existing
therapies. Pharmaceutical and biotechnology companies are at the forefront of
these efforts, dedicating substantial resources to discover and develop new
therapeutic options for diabetic retinopathy. This commitment to R&D
encompasses a wide array of activities, from exploring novel drug candidates
and improving current treatment modalities to developing advanced drug delivery
systems.
The process begins with the identification of
potential drug targets and the development of new compounds that could
effectively treat or manage diabetic retinopathy. Researchers are continually
investigating the underlying mechanisms of diabetic retinopathy, such as the
role of vascular endothelial growth factor (VEGF) in disease progression. This
research is critical for discovering new therapeutic targets and developing
drugs that can more precisely address the pathophysiology of the condition. For
instance, the advancement of anti-VEGF therapies has been a significant
breakthrough in diabetic retinopathy treatment, offering patients improved
outcomes by inhibiting abnormal blood vessel growth and reducing retinal fluid
leakage.
Clinical trials play a central role in R&D for
diabetic retinopathy. These trials test the safety and efficacy of new
therapies, providing valuable data that helps refine treatment approaches and
establish new standards of care. The rigorous testing involved in clinical
trials ensures that only the most effective and safest therapies reach the market.
Successful trials lead to regulatory approvals, allowing new treatments to
become available to patients and healthcare providers. Ongoing research studies
often focus on optimizing existing therapies, such as refining dosage regimens,
improving drug delivery methods, and reducing side effects. This continuous
improvement helps enhance the overall effectiveness of treatments and patient
adherence. The investment in R&D also fosters collaboration between
academia and industry, creating a synergistic environment that accelerates
innovation. Academic researchers often contribute foundational knowledge and
early-stage discoveries, which pharmaceutical and biotechnology companies can
then translate into clinical applications. These partnerships facilitate the
development of new therapeutic strategies and bring together diverse expertise
to tackle complex challenges in diabetic retinopathy care. Collaborative
efforts can lead to breakthroughs in understanding disease mechanisms,
discovering new drug candidates, and developing innovative treatment
technologies.
Patient Preference for Minimally Invasive
Procedures
The growing patient preference for minimally
invasive procedures is significantly shaping the diabetic retinopathy
therapeutic market. This trend reflects a broader shift in healthcare towards
treatments that provide effective outcomes while minimizing patient discomfort
and promoting faster recovery. As patients and healthcare providers
increasingly favor less invasive options, the diabetic retinopathy market is
evolving to meet these demands with advanced therapies and technologies. Minimally
invasive procedures have become highly desirable due to their potential to
offer several key benefits over traditional methods. For diabetic retinopathy,
which is characterized by damage to the blood vessels of the retina due to
prolonged high blood sugar levels, patients are particularly interested in
treatments that reduce the physical burden and risk associated with more
invasive approaches. Among the various minimally invasive options, intravitreal
injections and advanced laser treatments are leading the way.
Intravitreal injections involve delivering
therapeutic agents directly into the vitreous humor of the eye. These
injections are typically used to administer anti-VEGF (vascular endothelial
growth factor) drugs, which are effective in reducing retinal swelling and
abnormal blood vessel growth associated with diabetic retinopathy. The
minimally invasive nature of these injections—often performed with a fine needle
and under local anesthesia—makes them appealing to patients. The procedure
generally involves a shorter recovery time compared to traditional surgeries,
and patients can often resume normal activities quickly. The risk of
complications is lower, and the precision of the injection allows for targeted
treatment that can effectively manage or even improve the condition without
extensive disruption to the eye's structure. Advanced laser treatments also
align with the preference for minimally invasive procedures. Techniques such as
focal laser photocoagulation and pan retinal photocoagulation have seen
significant technological advancements. Modern laser systems offer greater
precision and reduced discomfort compared to older methods. Focal laser therapy
targets specific areas of the retina that require treatment, while pan retinal
laser therapy addresses widespread retinal damage. Both techniques are designed
to minimize damage to surrounding healthy tissue and reduce the risk of
complications. Innovations such as shorter laser pulses and improved delivery
systems have further enhanced the effectiveness and comfort of these
treatments.
Segmental Insights
Type Insights
Based on the type, proliferative
diabetic retinopathy (PDR) is currently more dominant compared to
non-proliferative diabetic retinopathy (NPDR). This dominance is driven by
several factors, including the severity of the condition, its impact on patient
quality of life, and the corresponding therapeutic needs. Proliferative
diabetic retinopathy represents the advanced stage of diabetic retinopathy and
is characterized by the growth of new, abnormal blood vessels on the retina and
the vitreous humour. These newly formed vessels are fragile and prone to
leakage, which can lead to severe complications such as retinal haemorrhage,
retinal detachment, and significant vision loss. The severity of PDR
necessitates more intensive and immediate therapeutic interventions, thereby
driving the demand for advanced treatments and technologies in the market.
The prevalence of PDR in
Japan has been increasing, partly due to the rising incidence of diabetes and
the aging population. As the diabetic population grows, so does the number of
individuals experiencing complications associated with diabetes, including PDR.
This trend is particularly concerning as PDR is more likely to cause
significant visual impairment compared to non-proliferative diabetic
retinopathy. Consequently, healthcare providers and patients prioritize
treatments that address the more severe manifestations of diabetic retinopathy,
leading to a greater focus on PDR within the therapeutic market. The
therapeutic management of PDR typically involves advanced treatment modalities
such as anti-VEGF (vascular endothelial growth factor) therapy, laser
photocoagulation, and vitrectomy. Anti-VEGF agents, such as ranibizumab and
aflibercept, have become cornerstone treatments for PDR due to their ability to
inhibit abnormal blood vessel growth and reduce retinal edema. Laser
photocoagulation, including panretinal photocoagulation (PRP), is used to
destroy abnormal blood vessels and reduce the risk of further retinal damage.
In more severe cases, vitrectomy may be required to address retinal detachment
or severe vitreous hemorrhage. The complexity and advanced nature of these
treatments highlight the market's focus on managing PDR and driving innovations
in therapeutic approaches.
Management Insights
Based on Management, anti-VEGF
(vascular endothelial growth factor) therapy is currently the dominant
treatment modality, surpassing other approaches such as intraocular steroid
injection, laser surgery, and vitrectomy. This dominance is attributed to
several key factors, including the efficacy of anti-VEGF agents in addressing
the underlying pathology of diabetic retinopathy, the high clinical demand for
effective treatment options, and the ongoing advancements in therapeutic
technologies. Anti-VEGF therapy has revolutionized the management of diabetic
retinopathy, particularly for proliferative diabetic retinopathy (PDR) and
diabetic macular edema (DME), which are among the most severe complications of
diabetes. These conditions are characterized by the abnormal growth of blood
vessels and increased vascular permeability in the retina, leading to
significant vision impairment and potential vision loss. Anti-VEGF agents, such
as ranibizumab (Lucentis), aflibercept (Eylea), and brolucizumab (Beovu),
specifically target and inhibit the activity of VEGF, a key growth factor
involved in the formation of these abnormal blood vessels.
The effectiveness of
anti-VEGF therapy in improving visual outcomes and stabilizing retinal
conditions has made it the preferred choice for treating diabetic retinopathy.
Clinical trials and real-world studies have demonstrated that anti-VEGF agents
can significantly reduce retinal edema, improve visual acuity, and prevent
further vision deterioration. This has led to widespread adoption of anti-VEGF
therapy in Japan, as it offers a minimally invasive approach with a high
therapeutic benefit compared to other treatment modalities. Intraocular steroid
injections, such as those involving triamcinolone acetonide or dexamethasone
implants, are another important treatment option for diabetic retinopathy,
particularly for managing diabetic macular edema. While they are effective in
reducing inflammation and controlling edema, they are generally considered less
effective than anti-VEGF therapy for long-term management of diabetic
retinopathy. Steroids are often used as adjunctive treatments or when patients
are not responsive to anti-VEGF agents. However, their use is associated with
potential side effects, such as elevated intraocular pressure and cataract
formation, which can limit their long-term application.
Download Free Sample Report
Regional Insights
The Kanto region dominated area,
driven by its substantial population size, advanced healthcare infrastructure,
and high prevalence of diabetes and its complications. The Kanto region, which
includes Tokyo, Yokohama, and other major cities, is at the forefront of
healthcare innovation and treatment accessibility, making it a key player in
the management of diabetic retinopathy. The Kanto region, home to over 40
million people, has a significant proportion of Japan's diabetic population.
This high population density contributes to a larger number of individuals
affected by diabetic retinopathy, driving the demand for therapeutic
interventions. The prevalence of diabetes is notably high in this region,
reflecting broader national trends exacerbated by lifestyle factors such as
urbanization and dietary changes.
Kanto boasts some of the most advanced healthcare
facilities in Japan. The region is home to numerous leading hospitals, research
institutions, and specialized clinics focused on diabetes and its
complications. Institutions like the University of Tokyo Hospital and Keio
University Hospital are known for their cutting-edge research and comprehensive
care for diabetic retinopathy. The concentration of specialized healthcare
providers and advanced treatment options in Kanto supports the region's
dominance in the market, as patients have better access to innovative therapies
and management strategies. The Kanto region is a hub for medical research and
innovation, with a strong presence of pharmaceutical and biotechnology
companies. The concentration of research institutions, such as the National
Center for Global Health and Medicine and various university-affiliated
research centers, fosters an environment conducive to the development and
adoption of new treatments for diabetic retinopathy. The presence of these
institutions accelerates the introduction of advanced therapies, such as
anti-VEGF agents and novel drug delivery systems, contributing to the region's
leadership in the therapeutic market.
Recent Developments
- According to a study in, “Associated
factors of diabetic retinopathy by artificial intelligence evaluation of fundus
images in Japan”, this cross-sectional study aimed to explore both promoting
and inhibitory factors related to diabetic retinopathy (DR) based on the stage
of diabetes mellitus (DM) through the use of artificial intelligence (AI) for
standardized fundus image evaluation. The study involved 30,167 participants
who underwent blood and fundus examinations at a health screening facility in
Japan between 2015 and 2016. AI software, specifically RetCAD, was used to
analyze fundus photographs and quantify DR scores (DRSs). DR presence was
determined by setting two distinct cut-off values to prioritize either
sensitivity or specificity. Diabetes mellitus was categorized into four stages
(no DM: DM0; advanced DM: DM3) based on treatment history and hemoglobin A1c
(HbA1c) levels. Logistic regression analysis was employed to identify factors
associated with DR.
- According to a study in, “Association
between retinopathy and risk of dementia in a general Japanese population: the
Hisayama Study”, the study examined the relationship between retinopathy and
the risk of dementia in a general population of older Japanese individuals. A
total of 1,709 residents aged 60 and older, who were free of dementia at the
start, were followed for 10 years from 2007 to 2017. In 2007, participants
underwent color fundus photography, and their retinopathy was classified using
the Modified Airlie House Classification. The primary outcome was the incidence
of dementia. To assess the risk, a Cox proportional hazards model was utilized
to calculate hazard ratios (HRs) and their 95% confidence intervals (CIs) for
dementia risk associated with retinopathy. Over the follow-up period, 374
participants developed all-cause dementia. The cumulative incidence of dementia
was notably higher in those with retinopathy compared to those without (p <
0.05). After adjusting for potential confounding factors, individuals with
retinopathy had a significantly increased risk of developing dementia (HR 1.64,
95% CI 1.19–2.25).
- According to a study in, “Associations
between fatty acid intake and diabetic retinopathy in a Japanese population”, The
study explored the link between retinopathy and dementia risk among older
Japanese individuals. It followed 1,709 people aged 60 and above, who were free
of dementia at the beginning, over a 10-year period from 2007 to 2017.
Retinopathy was assessed using color fundus photography and classified based on
the Modified Airlie House Classification. The research found that individuals
with retinopathy had a significantly higher risk of developing dementia
compared to those without retinopathy. During the study, 374 participants
developed dementia, and those with retinopathy showed a notably higher
cumulative incidence of the condition. After adjusting for confounding factors,
the risk of dementia was 64% higher for those with retinopathy.
Key Market Players
- AbbVie GK
- Novartis Pharma K.K.
- Eli Lilly Japan K.K..
- Kowa Company Ltd.
- Chugai Pharmaceutical Co., Ltd.
- Santen Pharmaceutical Co., Ltd.
- CLEA Japan, Inc.
- Senju Pharmaceutical Co., Ltd.
- Kubota Pharmaceutical Holdings Co., Ltd.
- Shionogi Pharmaceutical Co., Ltd
|
By Type
|
By Management
|
By Region
|
- Proliferative DR
- Non-proliferative DR
|
- Anti-VEGF Therapy
- Intraocular Steroid Injection
- Laser Surgery
- Vitrectomy
|
- Hokkaido
- Tohoku
- Kanto
- Chubu
- Kansai
- Chugoku
- Shikoku
- Kyushu
|
Report Scope:
In this report, the Japan Diabetic Retinopathy
Therapeutic Market has been segmented into the following categories, in
addition to the industry trends which have also been detailed below:
- Japan Diabetic Retinopathy Therapeutic
Market, By
Type:
o Proliferative DR
o Non-proliferative DR
- Japan Diabetic Retinopathy
Therapeutic Market, By
Management:
o Anti-VEGF Therapy
o Intraocular Steroid
Injection
o Laser Surgery
o Vitrectomy
- Japan Diabetic Retinopathy
Therapeutic Market, By
Region:
o Hokkaido
o Tohoku
o Kanto
o Chubu
o Kansai
o Chugoku
o Shikoku
o Kyushu
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the Japan Diabetic Retinopathy Therapeutic Market.
Available Customizations:
Japan Diabetic Retinopathy Therapeutic Market report
with the given market data, TechSci Research offers customizations according to
a company's specific needs. The following customization options are available
for the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
Japan Diabetic Retinopathy Therapeutic Market is
an upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at [email protected]